[CAS NO. 546141-08-6] URB597

Name: URB597
Brand: Arctom Scientific
SKU: SLK-S2631

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [546141-08-6]

Store

Catalog

SLK-S2631

Brand

Selleck

CAS

546141-08-6

DESCRIPTION [546141-08-6]

Overview

MDL	-
Molecular Weight	338.4
Molecular Formula	C20H22N2O3
SMILES	C(N)(=O)C=1C=C(C=CC1)C2=CC(OC(NC3CCCCC3)=O)=CC=C2

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	2.9551 mL	14.7754 mL	29.5508 mL
5 mM	0.5910 mL	2.9551 mL	5.9102 mL
10 mM	0.2955 mL	1.4775 mL	2.9551 mL
50 mM	0.0591 mL	0.2955 mL	0.5910 mL

Description

URB597 (KDS-4103) is a potent, orally bioavailable inhibitor with of 4.6 nM, with no activity on other cannabinoid-related targets. Phase 1.

Targets

FAAH ^[1]

4.6 nM

In vitro

URB597 binds in the hydrophobic pocket and catalytic core of FAAH that connects the active site residues to the membrane surface of FAAH. URB597 inhibits FAAH activity in human liver microsomes with IC50 of 3 nM. URB597 reduces the expression of the LPS-induced enzymes cyclo-oxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS; NOS2) in primary rat microglial cell, with a concomitant reduction in the release of the inflammatory mediators prostaglandin E2 (PGE2) and (NO) nitric oxide. URB597 evokes Ca entry in HEK293-F Cells transiently expressing human or rat TRPA1 gene. URB597 also activates Ca entry in rat DRG neurons natively expressed TRPA1 channels.

In vivo

URB597 inhibits [H]anandamide hydrolysis in rat brain membranes with a parallel increase in brain anandamide, OEA, and PEA content by inhibition of FAAH. URB597 enhances the hypothermia effect induced by ethanolamide by inhibiting FAAH. When delivered intraperitonealy (0.3 mg/kg) URB597 reduces allodynia and hyperalgesia through cannabinoid CB1 and CB2 receptor-mediated analgesia in rats with inflammatory pain. URB597 reduces the reduction in body weight gain and sucrose intake induced by the chronic mild stress in rats through inhibition of brain FAAH activity. URB597 could reverse most depressive-like symptoms induced by adolescent THC exposure in femal rats.

References

[1] Mor M, et al. J Med Chem, 2004, 47(21), 4998-5008.
[2] Piomelli D, et al. CNS Drug Rev, 2006, 12(1), 21-38.
[3] Tham CS, et al. FEBS Lett, 2007, 581(16), 2899-2904.
[4] Niforatos W, et al. Mol Pharmacol, 2007, 71(5), 1209-1216.
[5] Fegley D, et al. J Pharmacol Exp Ther, 2005, 313(1), 352-358.
[6] Jayamanne A, et al. Br J Pharmacol, 2006, 147(3), 281-288.
[7] Bortolato M, et al. Biol Psychiatry, 2007, 62(10), 1103-1110.
[8] Realini N, et al. Neuropharmacology, 2011, 60(2-3), 235-243.

Synonyms

Carbamic acid, N-cyclohexyl-, 3′-(aminocarbonyl)[1,1′-biphenyl]-3-yl ester

Carbamic acid, cyclohexyl-, 3′-(aminocarbonyl)[1,1′-biphenyl]-3-yl ester

3′-(Aminocarbonyl)[1,1′-biphenyl]-3-yl N-cyclohexylcarbamate

URB 597

KDS 4103

Org 231295

[3-(3-Carbamoylphenyl)phenyl] N-cyclohexylcarbamate

3′-Carbamoyl-[1,1′-biphenyl]-3-yl cyclohexylcarbamate